Suppr超能文献

青春期抑制和性别肯定激素治疗对性别焦虑青少年肾上腺雄激素的影响。

Changes in Adrenal Androgens During Puberty Suppression and Gender-Affirming Hormone Treatment in Adolescents With Gender Dysphoria.

机构信息

Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands; Department of Pediatric Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.

Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

J Sex Med. 2018 Sep;15(9):1357-1363. doi: 10.1016/j.jsxm.2018.07.017.

Abstract

INTRODUCTION

Gender-affirming hormone treatment is known to affect adrenal androgen levels in adult individuals with gender dysphoria (GD). This may be clinically relevant because the adrenal gland plays a critical role in many different metabolic processes.

AIM

This study aims to assess the effects of gonadotropin-releasing hormone analogs (GnRHa) treatment and gender-affirming hormone treatment on adrenal androgen levels in adolescents with GD.

METHODS

In this prospective study, dehydroepiandrosterone-sulfate (DHEAS) and androstenedione values were measured every 6 months during 2 years of GnRHa treatment only, and 2 years of GnRHa combined with gender-affirming hormone treatment (estradiol or testosterone) in 73 transgirls and 54 transboys. To determine trends in adrenal androgen levels a linear mixed model was used to approximate androgen levels.

MAIN OUTCOME MEASURES

DHEAS and androstenedione levels were the main outcome measures.

RESULTS

DHEAS levels rose in transboys during GnRHa treatment, which may represent the normal increase during adolescence. In transgirls no change in DHEAS levels during GnRHa treatment was found. Gender-affirming hormone treatment did not affect DHEAS levels in either sex. In transboys androstenedione levels decreased during the first year of GnRHa treatment, which may reflect reduced ovarian androstenedione synthesis, and rose during the first year of gender-affirming hormone treatment, possibly due to conversion of administered testosterone. In transgirls androstenedione levels did not change during either GnRHa or gender-affirming hormone treatment.

CLINICAL IMPLICATIONS

No deleterious effects of treatment on adrenal androgen levels were found during approximately 4 years of follow-up.

STRENGTHS & LIMITATIONS: This is one of the largest cohort of adolescents with GD, treated using a uniform protocol, with standardized follow-up. The lack of a control group is a limitation.

CONCLUSION

The changes in androstenedione levels during GnRHa and gender-affirming hormone treatment in transboys may not be of adrenal origin. The absence of changes in androstenedione levels in transgirls or DHEAS levels in either sex during gender-affirming hormone treatment suggests that gender-affirming hormone treatment does not significantly affect adrenal androgen production. Schagen SEE, Lustenhouwer P, Cohen-Kettenis PT, et al. Changes in Adrenal Androgens During Puberty Suppression and Gender-Affirming Hormone Treatment in Adolescents With Gender Dysphoria. J Sex Med 2018;15:1357-1363.

摘要

介绍

已知性别肯定激素治疗会影响有性别焦虑症(GD)的成年个体的肾上腺雄激素水平。这在临床上可能很重要,因为肾上腺在许多不同的代谢过程中起着关键作用。

目的

本研究旨在评估促性腺激素释放激素类似物(GnRHa)治疗和性别肯定激素治疗对 GD 青少年肾上腺雄激素水平的影响。

方法

在这项前瞻性研究中,在 GnRHa 治疗的 2 年内(仅)以及 GnRHa 联合性别肯定激素治疗(雌二醇或睾酮)的 2 年内,每 6 个月测量 73 名跨性别女孩和 54 名跨性别男孩的脱氢表雄酮硫酸盐(DHEAS)和雄烯二酮值。为了确定肾上腺雄激素水平的趋势,使用线性混合模型来近似雄激素水平。

主要观察指标

DHEAS 和雄烯二酮水平是主要观察指标。

结果

在 GnRHa 治疗期间,跨性别男孩的 DHEAS 水平升高,这可能代表青春期的正常升高。在跨性别女孩中,GnRHa 治疗期间未发现 DHEAS 水平发生变化。在任何性别中,性别肯定激素治疗均未影响 DHEAS 水平。在跨性别男孩中,雄烯二酮水平在 GnRHa 治疗的第一年下降,这可能反映出卵巢雄烯二酮合成减少,而在性别肯定激素治疗的第一年增加,可能是由于给予的睾酮的转化。在跨性别女孩中,GnRHa 或性别肯定激素治疗期间,雄烯二酮水平均未发生变化。

临床意义

在大约 4 年的随访期间,未发现治疗对肾上腺雄激素水平有任何不良影响。

优点和局限性

这是 GD 青少年最大的队列之一,使用统一的方案进行治疗,具有标准化的随访。缺乏对照组是一个限制。

结论

GnRHa 和性别肯定激素治疗期间,跨性别男孩的雄烯二酮水平变化可能不是肾上腺源性的。在跨性别女孩或任何性别中,性别肯定激素治疗期间的雄烯二酮水平或 DHEAS 水平均未发生变化,表明性别肯定激素治疗不会显著影响肾上腺雄激素的产生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验